Stryker remains a buy despite Q1 hit from cyberattack, with strong dividend growth and undervalued stock price.
Stryker, a medical technology leader and Dividend Aristocrat with 32 years of dividend increases, faced a cybersecurity incident impacting its Q1 2026 results. Despite this, management upheld its full-year guidance and expects business normalization ...
